Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07743580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

StatusRecruiting
PhasePhase 3
SponsorShionogi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 39 to 40
  2. Study sites: 37 to 39
  3. Trial sites expanded: 34 → 37 locations
    • Start date changed from estimate of Aug 31, 2026 to Sep 14, 2026
  4. Start date changed from estimate of Aug 31, 2026 to Sep 14, 2026
    • Eligibility criteria expanded, about 21 words
    • Site details revised at 1 of 34 sites
  5. Trial sites expanded: 27 → 34 locationsv3
  6. Recruitment opened
    • Start date: Aug 6, 2026 to Aug 31, 2026
    • Secondary endpoints: details revised at 2 of 15 entries
    • Site details revised at 27 of 27 sites
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Shionogi
45 trials monitored
See 2 trials at risk
The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.
Trial Details
NCT Number NCT07743580
Lead Sponsor Shionogi
Conditions
(from sponsor)		 SARS-CoV-2
Related terms COVID-19
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov